{"product_id":"viatris-business-model-canvas","title":"Viatris Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViatris's Business Model Unveiled!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Viatris's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003cp\u003eDive deeper into Viatris’s real-world strategy with the complete Business Model Canvas. From value propositions to cost structure, this downloadable file offers a clear, professionally written snapshot of what makes this company thrive—and where its opportunities lie.\u003c\/p\u003e\n\u003cp\u003eWant to see exactly how Viatris operates and scales its business? Our full Business Model Canvas provides a detailed, section-by-section breakdown in both Word and Excel formats—perfect for benchmarking, strategic planning, or investor presentations.\u003c\/p\u003e\n\u003cp\u003eGain exclusive access to the complete Business Model Canvas used to map out Viatris’s success. This professional, ready-to-use document is ideal for business students, analysts, or founders seeking to learn from proven industry strategies.\u003c\/p\u003e\n\u003cp\u003eSee how the pieces fit together in Viatris’s business model. This detailed, editable canvas highlights the company’s customer segments, key partnerships, revenue strategies, and more. Download the full version to accelerate your own business thinking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances \u0026amp; Joint Ventures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eViatris actively forms strategic alliances and joint ventures, especially for co-development and commercialization of complex products like biosimilars. These partnerships, exemplified by collaborations such as those involving their biosimilar portfolio, leverage complementary expertise and share the significant costs and risks associated with product development and regulatory approval. This approach is crucial for expanding their pipeline in high-growth areas, with Viatris projecting biosimilar revenues to reach approximately $1 billion by 2024, emphasizing the financial impact of these alliances. Such collaborations allow Viatris to bring innovative and affordable medicines to market more efficiently.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive Pharmaceutical Ingredient (API) Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA robust network of global Active Pharmaceutical Ingredient suppliers is crucial for Viatris's large-scale generic drug manufacturing, which saw net sales of $3.6 billion in Q1 2024. These partnerships prioritize cost-efficiency and stringent quality control, ensuring product integrity. Supply chain resilience is key to uninterrupted production. Diversifying suppliers mitigates geopolitical and logistical risks, safeguarding the availability of essential medicines worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers and Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViatris strategically partners with leading pharmaceutical wholesalers and distributors like McKesson, AmerisourceBergen, and Cardinal Health. These crucial alliances form the logistical backbone, ensuring Viatris products efficiently reach a vast network of pharmacies, hospitals, and clinics across the globe. For instance, in 2024, these distributors collectively managed over 90% of pharmaceutical sales in the U.S., highlighting their critical role. Such relationships are indispensable for Viatris's extensive market penetration and consistent product availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and Pharmacy Benefit Managers (PBMs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEstablishing strong relationships with government payers, private insurers, and Pharmacy Benefit Managers (PBMs) is crucial for Viatris to secure favorable formulary placement. This ensures widespread patient access and drives significant volume for their diverse portfolio of generic and branded products. These negotiations directly impact Viatris's market share and overall profitability, especially as PBMs influence over 80% of prescription drug claims in the United States as of 2024. For instance, in 2024, Viatris continued to navigate complex PBM contracts, aiming to maintain competitive access for key medications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePBMs manage over 80% of U.S. prescription drug claims in 2024, highlighting their influence.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFormulary inclusion directly impacts patient access and product sales volume.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNegotiations with payers and PBMs are critical for Viatris's market share and profitability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFavorable formulary placement can lead to substantial revenue streams for both generic and branded pharmaceuticals.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Academia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with research institutions and academia provide Viatris access to early-stage innovation and scientific talent. These partnerships are crucial for fueling the R\u0026amp;D pipeline, particularly for new drug delivery technologies and complex formulations. Such alliances enable Viatris to enhance its extensive product lines, including generics and biosimilars, and explore new therapeutic areas for growth. For example, in 2024, Viatris continues to prioritize advancements in areas like ophthalmology and complex injectables.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAccesses cutting-edge scientific expertise and early-stage research.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAccelerates development of novel drug delivery systems and complex formulations.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eExpands existing product portfolio and explores new therapeutic domains.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSupports a robust R\u0026amp;D pipeline crucial for sustained market presence.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Billions in Revenue and Market Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViatris’s strategic alliances, including co-development ventures for biosimilars, are projected to yield approximately $1 billion in revenue by 2024. Partnerships with API suppliers ensure the $3.6 billion Q1 2024 generic sales are supported by a resilient supply chain. Key distributors manage over 90% of U.S. pharmaceutical sales in 2024, enabling vast market reach. Collaborations with PBMs, influencing over 80% of U.S. prescription claims in 2024, are vital for formulary access and profitability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eKey Role\u003c\/th\u003e\n\u003cth\u003e2024 Impact\/Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Alliances\u003c\/td\u003e\n\u003ctd\u003eCo-development, commercialization\u003c\/td\u003e\n\u003ctd\u003eBiosimilar revenue ~$1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI Suppliers\u003c\/td\u003e\n\u003ctd\u003eGeneric drug manufacturing\u003c\/td\u003e\n\u003ctd\u003eQ1 2024 net sales $3.6 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eMarket penetration, logistics\u003c\/td\u003e\n\u003ctd\u003eOver 90% U.S. pharma sales managed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/PBMs\u003c\/td\u003e\n\u003ctd\u003eFormulary access, sales volume\u003c\/td\u003e\n\u003ctd\u003eOver 80% U.S. Rx claims influenced\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA structured overview of Viatris' business model, detailing its approach to serving diverse patient and healthcare provider needs through a broad portfolio of accessible medicines.\u003c\/p\u003e\n\u003cp\u003eIt highlights Viatris' strategies for market access, distribution channels, and key partnerships to deliver quality, affordable healthcare solutions globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eViatris' Business Model Canvas acts as a pain point reliever by offering a clear, actionable framework to navigate the complex pharmaceutical landscape, enabling faster strategic adjustments and resource allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eViatris's core activity centers on high-volume, cost-effective manufacturing of diverse pharmaceuticals, including generics, branded drugs, and biosimilars. This involves complex process optimization across its global network, which included 35 manufacturing sites as of early 2024. Stringent quality control is paramount, ensuring compliance with global regulatory standards for products like those contributing to Viatris's over $15 billion in projected 2024 revenue. Efficiency in production is a primary driver of profitability, crucial for maintaining competitive pricing and maximizing output.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eViatris manages a highly complex global supply chain, a critical differentiator ensuring reliable access to essential medicines across over 165 countries. This intricate activity involves precise logistics, sophisticated inventory management, and accurate demand forecasting to source raw materials and deliver finished products. By optimizing its global network, which serves millions of patients, Viatris maintains a significant competitive advantage in the pharmaceutical sector. Their 2024 operational focus continues to leverage this robust infrastructure for efficient product distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating the complex global regulatory landscape is a core activity for Viatris, involving authorities like the FDA and EMA. This includes diligently filing new drug applications and maintaining over 3,000 existing product licenses worldwide as of early 2024. Ensuring all manufacturing and marketing practices strictly adhere to compliance standards, such as those governing quality and safety, is paramount. This robust regulatory expertise is critical for securing market access and effectively mitigating legal and operational risks, underpinning the company's ability to serve patients globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eViatris’s Research and Development (R\u0026amp;D) activities are intensely focused on cultivating a robust pipeline of new generics, complex generics, and biosimilars. This critical process involves meticulous formulation development, comprehensive bioequivalence studies, and rigorous clinical trials to substantiate product safety and efficacy. R\u0026amp;D is indispensable for continuous portfolio refreshment and ensuring sustainable future growth. For instance, Viatris reported R\u0026amp;D expenses of $156 million for the first quarter of 2024, underscoring their commitment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eViatris’s Q1 2024 R\u0026amp;D expenditure: $156 million.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePrimary focus: New generics, complex generics, and biosimilars.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eKey activities: Formulation development and clinical trials.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic importance: Portfolio refreshment and future growth.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eViatris employs targeted sales and marketing strategies, focusing on its diverse portfolio including branded products like Lipitor and Viagra. These efforts involve direct engagement with healthcare professionals and robust relationship management with institutional buyers to foster brand loyalty. Marketing campaigns are designed to sustain prescription volume and market share across key therapeutic areas globally.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eViatris reported Q1 2024 revenues of 3.6 billion USD.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTheir established brands segment, a key focus for marketing, generated 2.2 billion USD in Q1 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSales teams engage thousands of healthcare providers worldwide.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharma Operations: Driving Health Access and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViatris's core activities include high-volume pharmaceutical manufacturing across 35 global sites and intricate supply chain management, ensuring product availability in over 165 countries. Rigorous R\u0026amp;D, with $156 million invested in Q1 2024, drives new product development, especially generics and biosimilars. Navigating complex global regulations and maintaining over 3,000 product licenses is critical for market access. Targeted sales and marketing efforts support revenue generation, contributing to Q1 2024 revenues of $3.6 billion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey Metric (2024)\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e35 global sites\u003c\/td\u003e\n\u003ctd\u003eCost-effective, high-volume production\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply Chain\u003c\/td\u003e\n\u003ctd\u003e165+ countries served\u003c\/td\u003e\n\u003ctd\u003eEnsures global product access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$156M (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eDrives portfolio innovation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e3,000+ product licenses\u003c\/td\u003e\n\u003ctd\u003eSecures market access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales \u0026amp; Marketing\u003c\/td\u003e\n\u003ctd\u003e$3.6B revenue (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eMaximizes market share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Viatris Business Model Canvas you are previewing is the actual, complete document you will receive upon purchase. This is not a sample or a mockup; it is a direct representation of the file, ready for your immediate use. Once your order is processed, you will gain full access to this entire Business Model Canvas, precisely as you see it displayed here, ensuring no surprises and full usability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55480461001081,"sku":"viatris-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/viatris-business-model-canvas.png?v=1752754106","url":"https:\/\/growthsharematrix.com\/products\/viatris-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}